AGN Stock News 158.58 05/15/2014 13:44:20 Allergan Inc (AGN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Allergan Inc (AGN) 158.58 $AGN

Encouraging Data on Eli Lilly's Necitumumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 44 mins ago
Eli Lilly (LLY) announced encouraging results on its lung cancer candidate necitumumab from a phase III study.

Novartis Settles Gleevec Patent Litigation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 10:40AM CDT
Novartis (NVS) has settled its litigation with the subsidiary of Sun Pharmaceutical Industries Ltd. in the U.S.

Merck KGaA Beats on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 10:20AM CDT
Merck KGaA (MKGAF) reported 1Q14 earnings per ADR of $3.17, up 13.6% year over year and ahead of the Zacks Consensus Estimate of $2.35.

Research and Markets: Latest Pharmaceuticals Manufacturers Report - Individual Analysis On The Top 200 Companies, Including Allergan Inc, A. Menarini - Industrie Farmaceutiche Riunite - S.R.L. & Boiron Sa
Business Wire - Thu May 15, 7:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tb4tpx/pharmaceuticals) has announced the addition of the "Pharmaceuticals Manufacturers (Global)" report to their offering.

Rejected Proposals, Earnings Results, and Financial Outlook - Analyst Notes on Allergan, Isis, Depomed, Lannett and Orexigen
PR Newswire - Thu May 15, 6:30AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), Depomed Inc. (NASDAQ: DEPO), Lannett Company, Inc. (NYSE: LCI) and Orexigen Therapeutics, Inc. (NYSE: OREX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2490-100free.

Latest Pharmaceuticals Manufacturers Report - Individual Analysis On The Top 200 Companies, Including Allergan Inc, A. Menarini - Industrie Farmaceutiche Riunite - S.R.L. & Boiron Sa
M2 - Thu May 15, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cc9ntj/pharmaceuticals) has announced the addition of the "Pharmaceuticals Manufacturers (Global)" report to their offering. PHARMACEUTICALS MANUFACTURERS (Global) Analysis provides a detailed overview of the PHARMACEUTICALS MANUFACTURERS (Global) market and delivers a comprehensive individual analysis on the top 200 companies, including ALLERGAN INC, A. MENARINI - INDUSTRIE FARMACEUTICHE RIUNITE - S.R.L. and BOIRON SA. This report includes a wealth of information on the financial trends over the past four years. Latest PHARMACEUTICALS MANUFACTURERS (Global) analysis is ideal for anyone wanting to: - See the market leaders - Identify companies heading for failure - Seek out the most attractive acquisition - Analyse industry trends - Benchmark their own financial performance A quick glance of this PHARMACEUTICALS MANUFACTURERS (Global) report will tell you that 25 companies have a declining Plimsoll financial rating, while 47 have shown good sales growth. Each of the largest 200 companies is meticulously scrutinised in a one-page individual assessment and is analysed using the most up-to-date and current financial data. Every business is examined on the following features: - The Plimsoll Chart: A graphical assessment of a company's financial performance - Four year assessment of the profit/loss and balance sheet - A written summary highlighting key performance issues This section includes: - Best Trading Partners - Sales Growth Analysis - Profit Analysis - Market Size - Rankings For more information visit http://www.researchandmarkets.com/research/cc...aceuticals

Merck Continues to Divest Ophthalmology Products - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 14, 4:00PM CDT
Merck (MRK) entered into an agreement with Santen Pharmaceutical Co. to divest its ophthalmology products.

Allergan Up 27.0% Since SmarTrend Uptrend Call (AGN)
Comtex SmarTrend(R) - Wed May 14, 11:06AM CDT
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on April 15th, 2014 at $125.97. In approximately 4 weeks, Allergan has returned 27.03% as of today's recent price of $160.01.

Pershing Square Eyes Nonbinding Vote on Allergan Bid
at The Street - Wed May 14, 9:41AM CDT
Bill Ackman's activist hedge fund Pershing Square Capital Management expects Allergan shareholders will have an opportunity as soon as next month to consider its proposal to have the Irvine, Calif.-based company engage in discussions over Canada's...

Healthcare Buyout Mania: Now What?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed May 14, 9:32AM CDT
It feels like there's nothing to talk about in the pharmaceutical space these days other than the latest M&A bid. Just in the last day and a half, investors have seen news on five completed or proposed transactions. And I doubt the deal-making is...

Dr. Reddy's Misses Q4 Earnings Ests, Beats on Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 14, 9:30AM CDT
Dr. Reddy's Laboratories (RDY) reported fourth-quarter 2014 earnings per ADS of 47 cents, missing the Zacks Consensus Estimate of 52 cents.

Athersys Reports Wider-than-Expected Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 14, 9:04AM CDT
Athersys, Inc.'s (ATHX) first quarter 2014 net loss of 15 cents per share was wider than the Zacks Consensus Estimate of a loss of 9 cents.

Global Hyaluronic Acid Products Market Product Trends and Forecasts, 2019: Single-Injection, Three-Injection Cycle and Five-Injection Cycle Analysis
M2 - Wed May 14, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snvprr/hyaluronic_acid) has announced the addition of the "Hyaluronic Acid Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Some of the prominent players in the hyaluronic acid products market that have been profiled in this report include Allegran Inc., Anika Therapeutics, Inc., Merz Aesthetics, Inc., Sanofi (Genzyme) and Seikagaku. Hyaluronic acid (HA) is a unique non-sulfated glycosaminoglycan, distributed throughout the body in connective tissues, epithelial and neural tissues. Hyaluronic acid contributes significantly to cell proliferation and migration and is observed to be an integral component of the extracellular matrix. Hyaluronic acid has wide number of applications such as orthopedic surgery, rheumatology, ophthalmology, otolaryngology, dermatology and plastic surgery, wound healing and drug delivery. Hyaluronic acid products are segmented on the basis of treatment regimen into single-injection, three-injection cycle and five-injection cycle products. In addition, HA injectable can be utilized in a range of applications such as osteoarthritis, dermal fillers, ophthalmic surgery and vesicoureteral reflux (VUX). The major factors driving this market are increasing geriatric population globally, high awareness about anti-aging procedures, patient's preference for the treatment with minimum side-effects and rising demand for minimally invasive surgical procedures. In products segment, five-injection cycle products is the largest marketsegment and single-injection market segment is growing with highest CAGR during forecast period from 2013 to 2019. Hyaluronic acid products market is observing a global shift in usage of five-injection cycle to single-injection cycle treatment as there has been a considerable change in preference of patients towards short duration treatment. This shift in preference is mainly related to convenience of patients as they try to avoid side-effects such as redness, inflammation and itching experienced after every treatment and five-injection cycle is a prolonged treatment compared to single-injection. Dermal fillers is the largest market closely followed by osteoarthritis market and vesicoureteral reflux (VUR) applications market. VUR application market for hyaluronic acid products is growing at a highest CAGR during the forecast period from 2013 to 2019. The segment is mainly driven by aging population, high demand for minimally invasive surgical treatments and high awareness about beauty enhancements. Report Scope Hyaluronic Acid Products Market, by Products - Single-injection - Three-injection cycle - Five-injection cycle Hyaluronic Acid Products Market, by Applications - Osteoarthritis - Ophthalmic - Dermal Fillers - Vesicoureteral Reflux (VUR) Hyaluronic Acid Products Market, by Geography - North America - Europe - Asia-Pacific - Rest of the World (RoW) Companies Mentioned - Alcon, Inc. - Allergan, Inc. - Anika Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Ferring Pharmaceuticals, Inc. - Fidia Farmaceutici SpA - GALDERMA S.A. - Hyaltech Ltd. - LifeCore Biomedical LLC, - Meiji Seika Pharma Co., Ltd. - Merz Aesthetics, Inc. - Sanofi - Salix Pharmaceuticals, Inc. - Seikagaku Corporation - Shanghai Jingfeng Pharmaceutical Co., Ltd. - Smith & Nephew plc - TRB CHEMEDICA INTERNATIONAL SA - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/sn...ronic_acid

Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 14, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

Global Diabetic Retinopathy Clinical Trials Report 2014
M2 - Wed May 14, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t9jfks/diabetic) has announced the addition of the "Diabetic Retinopathy Global Clinical Trials Review, H1, 2014" report to their offering. Diabetic Retinopathy Global Clinical Trials Review, H1, 2014 provides data on the Diabetic Retinopathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Retinopathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Retinopathy. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Novartis AG - Pfizer Inc. - Valeant Pharmaceuticals International, Inc. - Allergan, Inc. - Takeda Pharmaceutical Company Limited - Eli Lilly and Company - AstraZeneca PLC - BCN Peptides, S.A. - National Eye Institute - University of Sao Paulo - National Taiwan University Hospital - Association for Innovation and Biomedical Research on Light and Image - Medical University of Vienna - Moorfields Eye Hospital NHS Foundation Trust - Diabetic Retinopathy Clinical Research Network - Shahid Beheshti University of Medical Sciences - HOSPITAL JUAREZ DE MEXICO - Federal University of Sao Paulo For more information visit http://www.researchandmarkets.com/research/t9jfks/diabetic

Levadex (Migraine) - Forecast and Market Analysis to 2023
M2 - Wed May 14, 3:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q5vtkm/levadex) has announced the addition of the "Levadex (Migraine) - Forecast and Market Analysis to 2023" report to their offering. The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile. Levadex is being developed by Allergan as an acute therapy for migraine. Levadex is a member of the ergot alkaloids class of acute migraine treatment. It contains a reformulation of the drug dihydroergotamine mesylate (DHE) in a proprietary Tempo inhaler that allows DHE to be rapidly absorbed from the pleural mucosa into the systemic circulation. DHE has been used to treat migraine attacks for decades, administered by intravenous infusion or nasal sprays. Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Levadex 9 Appendix For more information visit http://www.researchandmarkets.com/research/q5vtkm/levadex

Abbott's Promising Data on RADICAL Platform - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 13, 5:05PM CDT
Abbott Labs (ABT) announced positive interim data from the RApid Diagnosis of Infections in the CriticAlly IlL (RADICAL) study.

Shire to Acquire Lumena - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 13, 4:00PM CDT
In a bid to strengthen its rare disease portfolio, Shire (SHPG) entered into an agreement to acquire privately-held Lumena Pharmaceuticals.

DirecTV and Green Mountain are big market movers
AP - Tue May 13, 3:28PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:

S&P 500 Eclipses 1,900 for First Time, Dow Books Another All-Time High
at The Street - Tue May 13, 3:21PM CDT
The S&P 500 breaks above 1,900 for the first time and closes, along with the Dow, with a record high.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 58

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 318

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 140

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 661

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 570

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 43

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 265

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading

Top 5 Most Recently Viewed Articles

Realty ONE Group Wins Prestigious Tech100 Award for Innovation

Updated Category News Views 367

Realty ONE Group Receives HousingWire's 2025 Tech100 Award Realty ONE Group International, a leading lifestyle brand and one of the most rapidly expanding franchises in the real estate sector, has been recognized with the esteemed HousingWire's 2025 Tech100 Real Estate award. This award spotlights groundbreaking companies making strides in the industry. Innovative...

Continue Reading
Conifex Timber Inc. Plans Q4 2024 Results Call Announcement

Updated Category News Views 271

Conifex Timber Inc. Plans for Q4 2024 Results Conference Call Conifex Timber Inc. (TSX: CFF) is gearing up for an important event as it approaches the release of its fourth quarter 2024 financial results. Set to occur after the market closes, this significant announcement is slated for March 12, 2025. Following the release, a conference call has been scheduled for March...

Continue Reading
FASTSIGNS® Achieves Top Spot for Veterans Franchise Recognition

Updated Category News Views 214

FASTSIGNS® Earns Top Ranking for Franchise Opportunities for Veterans Leading recognition highlights commitment to supporting veterans in business. FASTSIGNS®, a prominent name in signs, graphics, and visual communications, has once again made waves by being named one of the top franchises for veterans, securing the fifth position out of 150. This acknowledgment by a...

Continue Reading
Krispy Kreme Investors Alerted to Class Action Lawsuit Opportunity

Updated Category News Views 209

Krispy Kreme's Class Action Lawsuit: What Investors Need to Know Levi & Korsinsky, LLP has taken an important step to inform investors regarding a class action securities lawsuit involving Krispy Kreme, Inc. (NASDAQ: DNUT). This legal action aims to represent shareholders who may have suffered losses due to alleged securities fraud. Understanding the Nature of the Class...

Continue Reading
Christina Lake Cannabis Delays Annual Financial Statements Until July

Updated Category News Views 212

Christina Lake Cannabis Faces Delays in Financial Filings Christina Lake Cannabis Corp. (CSE: CLC) has recently announced a significant delay in the filing of its annual financial statements. The company indicated that it will be unable to submit these critical documents, which include management's discussion and analysis along with the required certifications from its...

Continue Reading